Clinical indications for, and the future of, circulating tumor cells

Dominic H. Moon, Daniel P. Lindsay, Seungpyo Hong, Andrew Z. Wang

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalAdvanced Drug Delivery Reviews
Volume125
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Biomarkers
Drug Monitoring
United States Food and Drug Administration
Disease-Free Survival
Colorectal Neoplasms
Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Biopsy
DNA
Research

Keywords

  • Circulating tumor cells
  • Circulating tumor DNA
  • Clinical application
  • Clinical utility
  • Liquid biopsy
  • Predictive biomarker
  • Prognostic biomarker

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Clinical indications for, and the future of, circulating tumor cells. / Moon, Dominic H.; Lindsay, Daniel P.; Hong, Seungpyo; Wang, Andrew Z.

In: Advanced Drug Delivery Reviews, Vol. 125, 01.02.2018, p. 143-150.

Research output: Contribution to journalReview article

Moon, Dominic H. ; Lindsay, Daniel P. ; Hong, Seungpyo ; Wang, Andrew Z. / Clinical indications for, and the future of, circulating tumor cells. In: Advanced Drug Delivery Reviews. 2018 ; Vol. 125. pp. 143-150.
@article{a019bc558f3a456eae6a76a2865a8824,
title = "Clinical indications for, and the future of, circulating tumor cells",
abstract = "Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.",
keywords = "Circulating tumor cells, Circulating tumor DNA, Clinical application, Clinical utility, Liquid biopsy, Predictive biomarker, Prognostic biomarker",
author = "Moon, {Dominic H.} and Lindsay, {Daniel P.} and Seungpyo Hong and Wang, {Andrew Z.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.addr.2018.04.002",
language = "English (US)",
volume = "125",
pages = "143--150",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Clinical indications for, and the future of, circulating tumor cells

AU - Moon, Dominic H.

AU - Lindsay, Daniel P.

AU - Hong, Seungpyo

AU - Wang, Andrew Z.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.

AB - Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.

KW - Circulating tumor cells

KW - Circulating tumor DNA

KW - Clinical application

KW - Clinical utility

KW - Liquid biopsy

KW - Predictive biomarker

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=85045129013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045129013&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2018.04.002

DO - 10.1016/j.addr.2018.04.002

M3 - Review article

C2 - 29626548

AN - SCOPUS:85045129013

VL - 125

SP - 143

EP - 150

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -